QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
- 28 September 2020Portfolio NewsAVROBIO Receives Orphan Drug Designation from the European Medicines Agency for AVR-RD-02, an Investigational Gene Therapy for Gaucher Disease
- 28 September 2020Portfolio NewsQurAlis named as one of Fierce Biotech's 2020 Fierce 15
- 18 September 2020SV NewsSV Health Investors welcomes six new Venture Partners to the Biotech team
- 17 September 2020Portfolio NewsSchweiger Dermatology Group Acquires the New York Dermatology Practices of Lillian Graf, M.D. and Leopold Laufer, M.D.
- 15 September 2020Portfolio NewsSV Health Investors announces launch of biotech portfolio company, Cellinta and the Company’s appointment of Dr Soraya Bekkali as CEO
- 14 September 2020Portfolio NewsJet Health, Inc. Acquires Carrington Hospice Care, Inc.
- 8 September 2020Portfolio NewsBardy Diagnostics® Announces Appointment of Kevin Hykes as President and Chief Executive Officer
- 7 September 2020SV NewsSV Health Investors (SV) announces the appointment of Alex Badamchi-Zadeh PhD, strengthening their transatlantic Biotech team
- 3 September 2020SV NewsHouman Ashrafian contributes to BIA's guide to investing in the UK biotech sector
- 2 September 2020Portfolio NewsClarify Medical Now Approved as a MultiPlan Participating Provider
- 1 September 2020Portfolio NewsBicycle Therapeutics Announces First Patient Dosed in Oxurion’s Phase II Trial Using a Novel Bicycle®-based Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema
- 19 August 2020Portfolio NewsCentauri Health Solutions Announces Acquisition of HCFS